{"id":308899,"date":"2010-02-11T14:19:00","date_gmt":"2010-02-11T19:19:00","guid":{"rendered":"e2249889-c78b-43e3-9643-b1d7d4aa587b:394692"},"modified":"2010-02-11T14:19:00","modified_gmt":"2010-02-11T19:19:00","slug":"biovail-investors-take-wait-see-approach","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/308899","title":{"rendered":"Biovail investors take wait &amp; see approach"},"content":{"rendered":"<p>Shares in <a href=\"http:\/\/www.financialpost.com\/markets\/company\/index.html?symbol=BVF&amp;id=31697\" >Biovail Corp.<\/a> barely budged following news that it has acquired the U.S. and Canadian rights to commercialize a new drug for rapid treatment of agitation in patients with schizophrenia or<br \/>\nbipolar disorder. <\/p>\n<p> It&#39;s not that the deal doesn&#39;t look good, says Marc Goodman, UBS strategist. Its just too early to know just how good.<\/p>\n<p>&quot;This deal helps deepen Biovail\u2019s [central nervous system] pipeline. Biovail needs more shots on goal before investors start to give it credit for its pipeline. This is a good way to start the new year,&quot; the analyst said in a note to clients.&nbsp;<\/p>\n<p>He maintained his Buy rating and $16 price target, saying he needed to become more comfortable with the commercial potential of the drug. <\/p>\n<p>&quot;This drug is an interesting wild card. It works faster than orals and is less invasive than injections. At this point, we still need to determine how agitated most of these<br \/>patients are and whether inhalation is a viable option for most of them,&quot; he wrote. <\/p>\n<p><a href=\"mailto:dpett@nationalpost.com%20\">David Pett<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/network.nationalpost.com\/NP\/aggbug.aspx?PostID=394692\" width=\"1\" height=\"1\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shares in Biovail Corp. barely budged following news that it has acquired the U.S. and Canadian rights to commercialize a new drug for rapid treatment of agitation in patients with schizophrenia or bipolar disorder. It&#39;s not that the deal doesn&#39;t look good, says Marc Goodman, UBS strategist. Its just too early to know just how [&hellip;]<\/p>\n","protected":false},"author":4060,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-308899","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/308899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/4060"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=308899"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/308899\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=308899"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=308899"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=308899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}